Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Moore

Showing results (1381-1390 of 1,421) with videos related to

Pageof 143
Sort By:
Biorxiv : the Preprint Server for Biology|February 3, 2021
mRNA-1273 efficacy in a severe COVID-19 model: attenuated activation of pulmonary immune cells after challengeMichelle Meyer, Yuan Wang, Darin Edwards, et al.
The Lancet. Oncology|April 20, 2023
Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trialLinda R Mileshkin, Kathleen N Moore, Elizabeth H Barnes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 3, 2025
Dostarlimab and niraparib in primary advanced ovarian cancerA-C Hardy-Bessard, E Pujade-Lauraine, R G Moore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 22, 2020
MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary PeritoneumBradley J Monk, Rachel N Grisham, Susana Banerjee, et al.
The New England Journal of Medicine|March 9, 2012
Enzyme-replacement therapy in life-threatening hypophosphatasiaMichael P Whyte, Cheryl R Greenberg, Nada J Salman, et al.
Ecological Applications : a Publication of the Ecological Society of America|May 20, 2021
Landscape analyses using eDNA metabarcoding and Earth observation predict community biodiversity in CaliforniaMeixi Lin, Ariel Levi Simons, Ryan J Harrigan, et al.
JB & JS Open Access|March 17, 2025
Descriptive Epidemiology of Venous Thromboembolism in Pediatric Orthopedic Patients: A National, Multicenter StudyHillary Brenda Nguyen, Ryan M Sanborn, Danielle Cook, et al.
The Journal of Experimental Medicine|August 4, 2021
Eosinophils are part of the granulocyte response in tuberculosis and promote host resistance in miceAndrea C Bohrer, Ehydel Castro, Zhidong Hu, et al.
Plos Pathogens|January 23, 2025
Passive infusion of an S2-Stem broadly neutralizing antibody protects against SARS-CoV-2 infection and lower airway inflammation in rhesus macaquesChristopher T Edwards, Kirti A Karunakaran, Elijah Garcia, et al.
Gynecologic Oncology|July 1, 2026
Updated patient-reported outcomes and the effect of disease progression on health-related quality of life in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancerMark S Shahin, Domenica Lorusso, Floor J Backes, et al.
Pageof 143

Showing results (1381-1390 of 1,421) with videos related to

Sort By:
Pageof 143
Biorxiv : the Preprint Server for Biology|February 3, 2021
mRNA-1273 efficacy in a severe COVID-19 model: attenuated activation of pulmonary immune cells after challengeMichelle Meyer, Yuan Wang, Darin Edwards, et al.
The Lancet. Oncology|April 20, 2023
Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trialLinda R Mileshkin, Kathleen N Moore, Elizabeth H Barnes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 3, 2025
Dostarlimab and niraparib in primary advanced ovarian cancerA-C Hardy-Bessard, E Pujade-Lauraine, R G Moore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 22, 2020
MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary PeritoneumBradley J Monk, Rachel N Grisham, Susana Banerjee, et al.
The New England Journal of Medicine|March 9, 2012
Enzyme-replacement therapy in life-threatening hypophosphatasiaMichael P Whyte, Cheryl R Greenberg, Nada J Salman, et al.
Ecological Applications : a Publication of the Ecological Society of America|May 20, 2021
Landscape analyses using eDNA metabarcoding and Earth observation predict community biodiversity in CaliforniaMeixi Lin, Ariel Levi Simons, Ryan J Harrigan, et al.
JB & JS Open Access|March 17, 2025
Descriptive Epidemiology of Venous Thromboembolism in Pediatric Orthopedic Patients: A National, Multicenter StudyHillary Brenda Nguyen, Ryan M Sanborn, Danielle Cook, et al.
The Journal of Experimental Medicine|August 4, 2021
Eosinophils are part of the granulocyte response in tuberculosis and promote host resistance in miceAndrea C Bohrer, Ehydel Castro, Zhidong Hu, et al.
Plos Pathogens|January 23, 2025
Passive infusion of an S2-Stem broadly neutralizing antibody protects against SARS-CoV-2 infection and lower airway inflammation in rhesus macaquesChristopher T Edwards, Kirti A Karunakaran, Elijah Garcia, et al.
Gynecologic Oncology|July 1, 2026
Updated patient-reported outcomes and the effect of disease progression on health-related quality of life in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancerMark S Shahin, Domenica Lorusso, Floor J Backes, et al.
Pageof 143